Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Seguin, A. Guimond, E. Viau, P. Aube, P. Renzi, L. Paquet, N. Ferrari (Montreal/QC, Canada). Advantageous toxicity profile of novel inhaled antisense oligonucleotides, TPI ASM8 and TPI 1100, following chronic dosing in monkeys. Eur Respir J 2008; 32: Suppl. 52, 4191

Member's Comments

No comment yet.

Related content which might interest you: Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 The bronchodilator effects of the novel anti-inflammatory compound TPI 1020, alone and in combination with formoterol, in conscious guinea pigs Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Repeated daily inhalations of ciclesonide, compared to single inhalation, do not lead to increased systemic exposure Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006 Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002 Single-dose indacaterol, a novel 24-hour β2-agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006 Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 New method of treatment of steroid-dependant asthma with inhalations of ultra-low doses of alkylating drug: clinical results Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001 Feasibility, distribution, and efficacy of an inhaled oligonucleotide mimic of miR-29 for pulmonary fibrosis induced by bleomycin in rats Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Acute asthma treatment: comparison of formoterol and salbutamol given in cumulative doses in children Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Safety, efficacy and pharmacokinetics of inhaled TPI 1020 in smokers with asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011